[{"orgOrder":0,"company":"Symrise","sponsor":"Ceapro","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Avenanthramides","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Symrise","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Symrise \/ Symrise","highestDevelopmentStatusID":"12","companyTruncated":"Symrise \/ Symrise"}]

Find Clinical Drug Pipeline Developments & Deals by Symrise

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the agreement, Symrise is guaranteed to purchase minimum annual volumes of Ceapro’s high value active ingredients. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

                          Brand Name : Juvente

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 10, 2022

                          Lead Product(s) : Oat Beta Glucan,Avenanthramides

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Recipient : Ceapro

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank